Goldman Sachs Group Inc Ardelyx, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
Call Options
1 transactions
Others Institutions Holding ARDX
# of Institutions
222Shares Held
167MCall Options Held
517KPut Options Held
1.61M-
Black Rock Inc. New York, NY17.6MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$104 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X015.1MShares$98 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny11.7MShares$75.9 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C311.5MShares$74.6 Million0.06% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $1.01B
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...